286-300 of 894
Subcutaneous Isatuximab Matches IV in Multiple Myeloma: Insights from IRAKLIA
Project Oncology®Subcutaneous Isatuximab Matches IV in Multiple Myeloma: Insights from IRAKLIA
Marlene Mimi Maeusli, PhD.
Patient Perspectives on Subcutaneous vs IV Immunotherapies in Oncology Care
Project Oncology®Patient Perspectives on Subcutaneous vs IV Immunotherapies in Oncology Care
Ryan Quigley
From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
Project Oncology®From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
Project Oncology®Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
Ryan Quigley
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Project Oncology®Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Brian Slomovitz, MD
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Project Oncology®Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Brian Slomovitz, MD
- advertisement
Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
Project Oncology®Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Project Oncology®From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Putting Patients First: Personalized Care in Metastatic Breast Cancer
On the Frontlines of Metastatic Breast CancerPutting Patients First: Personalized Care in Metastatic Breast Cancer
Ashley Baker, MSN, PMHNP
Giancarlo Moscol, M.D.
Apremilast in Patients with a History of Cancer: A Five-Year Clinical Perspective
Clinician's RoundtableApremilast in Patients with a History of Cancer: A Five-Year Clinical Perspective
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
On the Frontlines of Metastatic Breast CancerClinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
Ashley Baker, MSN, PMHNP
Giancarlo Moscol, M.D.
DESTINY-Breast04 Findings: T-DXd and Quality of Life in HER2-Low Metastatic Breast Cancer
On the Frontlines of Metastatic Breast CancerDESTINY-Breast04 Findings: T-DXd and Quality of Life in HER2-Low Metastatic Breast Cancer
Marlene Mimi Maeusli, PhD.
- advertisement
Improving Metastatic Breast Cancer Care Through Integrated Palliative Support
On the Frontlines of Metastatic Breast CancerImproving Metastatic Breast Cancer Care Through Integrated Palliative Support
Ryan Quigley
Translating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
Heart MattersTranslating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Project Oncology®SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
